NewAmsterdam Pharma (NAMS) Accounts Payables (2021 - 2026)

NewAmsterdam Pharma has disclosed Accounts Payables across 6 years of filings, most recently posting $8.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $8.1 million, up 0.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (up 0.86% YoY), and the FY2025 annual result was $9.0 million, up 89.08% from the prior year.
• Accounts Payables came in at $8.1 million for Q1 2026 at NewAmsterdam Pharma, down from $9.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $22.7 million in Q2 2023 to a low of $4.7 million in Q4 2024.
• The 5-year median for Accounts Payables is $8.5 million (2025), against an average of $10.1 million.
• Across the five-year window, Accounts Payables tumbled 76.77% in 2024 and soared 89.08% in 2025, its largest moves.
• NewAmsterdam Pharma's Accounts Payables stood at $18.9 million in 2022, then tumbled by 39.62% to $11.4 million in 2023, then plunged by 58.38% to $4.7 million in 2024, then jumped by 89.08% to $9.0 million in 2025, then fell by 9.81% to $8.1 million in 2026.
• The last three Accounts Payables figures came in at $8.1 million (Q1 2026), $9.0 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.